- Background
- What we're looking for
- What we can offer you
- Who we are
- Q&A
Biological discovery workflows often require researchers to produce, isolate, characterize, and test large numbers of biological samples before useful data can be generated. Each sample may need to move through several labor-intensive steps, including quality control and downstream biochemical, biophysical, cellular, or phenotype screening.
As discovery programs scale, these workflows can become slow, repetitive, and resource-intensive. Manual handling across tubes, plates, filters, beads, columns, and assay formats can limit throughput, introduce variability, and make it difficult to process hundreds of samples consistently. This is especially challenging when early-stage research requires testing many constructs or conditions to identify biological products that express well, remain soluble and active, and are suitable for downstream screening.
High-throughput and automated laboratory systems are increasingly helping research teams address these bottlenecks by reducing hands-on time and enabling more scalable, reproducible protein production and screening workflows. Advances in flexible automation, integrated sample processing, automated protein characterization, rapid quality control, and miniaturized screening could help teams expand the number of targets and conditions they can explore while accelerating the path from protein production to actionable discovery data.
We are looking for technologies that automate and streamline high-throughput biological discovery workflows, enabling efficient processing, characterization, and screening of large numbers of recombinant protein, while reducing manual effort and accelerating the generation of reliable experimental results.
- Automated algae, tissue, or protoplast screening systems for early plant-relevant biological readouts
- Miniaturized assay platforms using automated nanoliter or low-volume dispensing
- Automated enzyme activity assay platforms for screening catalytic function
- Automated inhibitor screening platforms for testing compound effects on protein or enzyme activity
- Automated LC-MS or MS-based platforms for protein characterization, enzyme activity, compound transformation, or metabolite analysis
- Automated binding analysis platforms for protein-ligand, protein-protein, or target-compound interactions
- High-content imaging platforms for cellular, protoplast, tissue, or phenotypic screening workflows
- Automated whole-plant or seedling phenotyping systems for herbicide response and trait validation
- Reduces manual handling, hands-on time, or repetitive intervention compared with conventional workflows
- Supports parallel or high-throughput processing of multiple samples, variants, conditions, or assays
- Suitable for early-stage research workflows where protocols may vary
- Clear evidence of performance through case studies, validation data, benchmarks, or demonstrated use
- Adaptable to different assay formats, sample formats, biological targets, or workflow steps
- Designed to preserve sample quality, activity, stability, or integrity during automated processing or analysis
Bayer’s vision of #HealthForAll, #HungerForNone drives our need to strengthen innovation capabilities in all areas of agriculture. We know we can’t accomplish this alone, so we're always interested to hear about novel, early-stage scientific innovations that can contribute to feeding the world without starving the planet. You have our commitment to take a look, match with our R&D priorities and provide you timely feedback.
Learn moreThe Q&A is now closed.
Other recommended requests
delivered to your inbox.